'김갑성' 기자의 전체기사
-
Fosun Pharma Announces 2025Q3 Financial Results
[ 메디채널 김갑성 기자 ] Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters of 2025. In the first three quarters of 2025, Fosun Pharma achieved operating revenue of RMB29,393 million, net profit attributable to s
- 김갑성 기자
- 2025-10-28 20:11
-
South Korea's Leading Hair Loss Treatment Company, AESM…
[ 메디채널 김갑성 기자 ] AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL, South Korea, Oct. 28, 2025 -- AESMED Co., Ltd., a leading hair loss treatment company in South Korea, announced its participation in Cosmoprof Asia Hong Kong 2025, the largest B2B international beauty trade fair in Asia, to be held from November 12–14, 2025, at the Hong Kong Convention & Exhibition Centre. Cosmoprof Asia brings together global beauty leaders to present the latest technologies, product innovations, and solutions, serving as a key platform shaping the beauty industry worldwide.
- 김갑성 기자
- 2025-10-28 19:37
-
Myrio Therapeutics Announces Collaboration with Leading…
Myrio Therapeutics, the University of Pennsylvania Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to accelerate the development of next-generation T cell immunotherapies Partnership with T cell experts Daniel J Powell Jr., PhD, and Mark Yarmarkovich, PhD PHILADELPHIA, NEW YORK and MELBOURNE, Australia, Oct. 28, 2025 -- Myrio Therapeutics today announced a collaborative research partnership with the University of Pennsylvania's Perelman School of Medicine and NYU Langone Health to accelerate the development of next generation sol
- 김갑성 기자
- 2025-10-28 19:35
-
WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia a…
SHANGHAI, Oct. 28, 2025 -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northwest Saudi Arabia and the Ministry of Health of the Kingdom of Saudi Arabia (MOH). WuXi AppTec and NEOM have agreed to collaborate to explore the localization of pharmaceutical research, development and manufacturing in Saudi Arabia. The agreement lays the groundwork for establishing world-class CRDMO facilit
- 김갑성 기자
- 2025-10-28 17:00
-
Xinhua Silk Road: Innovation, tradition deeply integrated on…
BEIJING, Oct. 28, 2025 -- China's Zhangshu City, a famed industrial hub of traditional Chinese medicine (TCM) for centuries, has actively promoted integration of tradition and innovation for China's traditional medicines and medical treatment on its annual TCM fair. The 56th National Medicinal Materials and Pharmaceuticals Trade Fair, which was held on October 16-18 in Zhangshu City in east China's Jiangxi Province, provided a platform for TCM experts to exchange cutting-edge ideas on topics like protection of TCM resources and application of satellite remote sensing technology
- 김갑성 기자
- 2025-10-28 16:31
-
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(IN…
Results presented at the17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial hemorrhage occurred. Data suggest that LT3001 has the potential to provide significant clinical benefit to patients in a longer treatment window (up to 24 hours after the onset of stroke symptoms) compared to current standard of care (4.5 hours). TAIPEI, Oct. 28, 2025 -- Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) i
- 김갑성 기자
- 2025-10-28 16:28
-
Samsung Biologics reports third quarter 2025 financial results
Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion Recorded Q3'25 consolidated operating profit of KRW 728.8 billion Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the third quarter of fiscal year 2025. "Our third quarter results reflect the solid foundation we have built through operational excell
- 김갑성 기자
- 2025-10-28 14:50
-
Standard Foods Announces Strategic Partnership and Inve…
SINGAPORE, Oct. 28, 2025 -- Hello Health Group (HHG), Asia's leading digital health and wellness platform, and Standard Foods Group (SFG), a leading nutrition and health-related consumer goods company headquartered in Taiwan, are pleased to announce a strategic partnership, with SFG joining as a strategic investor in HHG's Pre-Series A investment round. This collaboration marks a significant milestone for both organizations as they unite their strengths to advance the future of digital health, nutrition, and preventive wellness across Southeast Asia. The partnership brings together SFG
- 김갑성 기자
- 2025-10-28 10:00
-
Alphamab Oncology Announces Biparatopic HER2-targeting…
SUZHOU, China, Oct. 28, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (PROC), not restricted by HER2 expression. This marks another accelerated review recognition for JSKN003 from an internationally authoritative regulatory agency, following two previous Breakthrough
- 김갑성 기자
- 2025-10-28 09:46
-
Onward Therapeutics Exercises Exclusive Option and Signs…
EPALINGES, Switzerland, Oct. 28, 2025 -- Onward Therapeutics SA, a clinical stage oncology company, today announced that its French subsidiary, Onward Therapeutics France, has exercised its exclusive option and entered into a worldwide license agreement with Institut du Cancer de Montpellier (ICM), France, to further advance a breakthrough program in onco-metabolism. This license agreement builds upon the exclusive collaboration and option agreement signed between Onward Therapeutics France and ICM, Inserm and Université de Montpellier in June 2021, under w
- 김갑성 기자
- 2025-10-28 08:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-13_SAT
- フォーミュラ1エティハド航空アブダビグランプリ（Formula 1 Etihad Airways Abu Dhabi Grand Prix）、ヤス島に339,000人のファンを動員 19:05
- SmallRig and FamilyLens Launch Global Family Filmmaking Initiative at 3rd FamilyLens International Film Festival 13:10
- 「FUJIYA」新ビジュアルアイデンティティと「Tenjincho Place」、2025年度台湾ゴールデンピンデザイン賞に輝く 10:47
- ALL CONEC Signs MOU with MINIMAX to Accelerate Global Digital Dental Expansion 08:00
- Introducing CASEKOO Rouge. The Gold Standard. 06:00
- NETMARBLE REVEALS NEW TRAILER FOR THE SEVEN DEADLY SINS: ORIGIN AT THE GAME AWARDS 2025 03:00
- Photography Awards and Sharing Session at the Palace Museum Highlight Mobile Imaging Technology as a Catalyst for Cultural Exchange 01:11
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 13일 20시 40분